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We report a 40-year-old female patient who was admit-
ted to the hospital because of a left ovarian mass torsion. A
nonhemolytic, nonmotile Bacillus, suspicious of Bacillus
anthracis, was isolated from a blood culture. We discuss
the evaluation that led to the final identification of the bac-
terium as B. megaterium. 
B
acillus represents a genus of ubiquitous gram-positive
bacteria. The species are used in many medical, phar-
maceutical, agricultural, and industrial processes, including
those for making antibiotics and insecticides (1–4). Even
the anthrax toxin is being evaluated as a choice for tumor
cell surface targeting in chemoresistant neoplasms (5). 
Although most species are harmless, two are medically
significant: Bacillus anthracis and B. cereus. B. anthracis
causes anthrax in its cutaneous, pulmonary (inhalational),
and intestinal forms. B. cereus causes two distinct food
poisoning syndromes, a rapid-onset emetic syndrome char-
acterized by nausea and vomiting and a slower onset diar-
rheal syndrome. 
Bacillus are often isolated on blood culture and usually
represent blood culture contamination. For example,
Bacillus species pseudobacteremia has been traced to con-
taminated gloves used in collection of blood from patients
(6). In immunocompromised hosts, a blood culture grow-
ing Bacillus species should be evaluated carefully. Rarely,
these species cause important clinical diseases such as bac-
teremia, sepsis, meningitis, pneumonia, empyema, oph-
thalmitis, osteomyelitis, endocarditis, soft tissue infection,
and intravascular catheter-acquired sepsis.
Pseudotumour of the lung has been reported as the
cause of infection with B. sphaericus (7). Endocarditis has
been reported to be caused by B. subtilis (8). An outbreak
of  Bacillus species in a cancer hospital in Brazil was
reported (9) and was strongly associated with use of calci-
um gluconate solution and central venous lines. The out-
break was controlled by stopping use of the implicated cal-
cium gluconate vials.
Case Study
A 40-year-old woman, with no significant medical his-
tory, was seen at the emergency room because of worsen-
ing left lower quadrant abdominal pain. The pain, which
had started a few days previously, was constant, localized
to the left lower quadrant of the abdomen, and described as
dull and moderately to severely intense. The pain was not
related to meals or bowel movements and was not accen-
tuated or relieved by any specific position. The patient
noted constipation but had no nausea or vomiting. No rec-
tal bleed or melena occurred, and she reported no urinary
symptoms or vaginal discharge. Her last normal menstrual
period was 8 days before. She felt warm but did not check
her temperature and did not experience chills. Her primary
medical physician prescribed ciprofloxacin 500 mg orally
twice a day for the presumptive diagnosis of colitis. She
took the antibiotic for 2 days without improvement.
In the emergency room, the patient was afebrile and
hemodynamically stable. The physical examination
showed tenderness on palpation of the left lower quadrant
of the abdomen with minimal rebound tenderness. The
pelvic examination showed left adnexal tenderness with a
possible mass. Results of urinalysis and a urine pregnancy
test were negative. No leukocytosis was noted. A pelvic
ultrasonograph showed a left ovarian complex mass meas-
uring 14 cm x 9 cm x 6 cm as well as a moderate amount
of free fluid in the cul-de-sac. The study suggested left
ovarian mass torsion. A laparascopic resection was per-
formed successfully. The patient received intravenous
cefazolin perioperatively. The final pathology report
showed a mature teratoma of the left ovary featuring der-
moid cyst, respiratory anlaga, and struma ovarii. The
patient improved and was discharged 2 days after surgery.
One day later, a blood culture, drawn in the emergency
room, grew nonhemolytic, nonmotile gram-positive rods.
B. anthracis was suspected. The blood culture was report-
ed to the New York City Department of Health. The patient
was called for reassessment at the hospital. She was
afebrile, and her only complaint was mild low back pain.
She had mild dry cough, but results of a chest
roentgenogram were unremarkable. She was started on
intravenous clindamycin, ciprofloxacin, and rifampin. Two
days later, the New York City Department of Health
reported the following: results of the direct fluorescent-
antibody (DFA) assay, using fluorescein-labeled mono-
clonal antibodies specific to the B. anthracis capsule
(CAP-DFA) antigens, were positive; results of the DFA
assay, using fluorescein-labeled monoclonal antibodies
specific to the B. anthracis cell wall (CW-DFA) were neg-
ative; and the Bacillus isolated was not lysed by the
γphage.
The organism was confirmed to be Bacillus non-
anthracis. Based on its characteristics, it was classified as
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*Staten Island University Hospital, Staten Island, New York, USAB. megaterium. The information was disclosed to the
patient, and the intravenous antibiotic therapy was discon-
tinued. The patient’s initial dry cough had resolved, and
she had no evidence of any cutaneous, respiratory, or neu-
rologic sign of disease. She was counseled about any
potential side effects of the antibiotic therapy she had
received, otherwise reassured, and then discharged. 
Conclusions
Presumptive identification of B. anthracis in a hospital
laboratory is based on the direct Gram-stained smear of a
skin lesion, cerebrospinal fluid, or blood showing encapsu-
lated, broad, gram-positive bacilli. Indicators of growth
apparent on cultures are also factors. B. anthracis is non-
motile and nonhemolytic on sheep’s-blood agar. In vitro it
grows as long chains, but in the host B. anthracis appears
as single organisms or chains of two or three bacilli. The
organism formsmucoid colonies and exhibits a prominent
capsule when grown on nutrient agar containing 0.7%
sodium bicarbonate in the presence of 5% to 20% carbon
dioxide (10).
The only nonmotile Bacillus are B. anthracis and B.
cereus subsp. mycoides. Some other Bacillus species show
variable motility and may often be nonmotile. These
species include B. megaterium, B. firmus, and B. circulans.
At the community laboratory level, once the Bacillus
colonies are identified as catalase-positive, nonhemolytic,
nonmotile gram-positive rods, the organism should be
packaged properly and transported to a state or county
public health laboratory for confirmation (11).
Confirmatory diagnostic tests are performed at the
Laboratory Response Network for Bioterrorism (LRN)
(11), which consists of laboratories at four levels (12–14).
Laboratories at the community level, considered level A,
should recognize the clues to a suspicious agent and pack-
age the agent for transfer to the next higher level labora-
tory. 
Level-B laboratories often include the state and county
public health laboratories. Criteria for confirming B.
anthracis at this level include susceptibility to lysis by
γphage and a two-component DFA assay, using cell wall
(CW-DFA) and capsule (CAP-DFA) antigens (11). The
two-component DFA assay is a sensitive, specific, and
rapid confirmatory test for B. anthracis in cultures (15,16).
The lysis by γ phage (17) is highly specific for B.
anthracis, and when demonstrated concomitantly with the
presence of a capsule, confirms the identification. The
New York City Department of Health protocol reports a
sample as positive only if it has all the following pheno-
types: nonmotile, penicillin sensitive, γ-phage positive,
and positive by both cell wall and CAP-DFA assays (11). 
The level-C laboratory has the capacity of the level-B
laboratory, plus antimicrobial susceptibility testing and
advanced detection methods. It also can help with surge
capacity and has much greater biosafety-level working
capacity. Advanced detection methods include time-
resolved fluorescence and polymerase chain reaction
(PCR) (14,18). These methods are employed to quickly
yield preliminary data in advance of the classical microbi-
ology final report (11). 
The level-D laboratory has the highest level of contain-
ment (biosafety level) and expertise in diagnosis. Various
tests to determine the molecular characteristics of isolates
are conducted, including molecular subtyping with multi-
locus variable-number tandem repeat analysis and
sequencing of genes coding for 16S ribosomal RNA
(19,20). The analysis allows for identification of a particu-
lar pattern that can be associated with geographic, tempo-
ral, or other relevant epidemiologic designations. The
Centers for Disease Control and the U. S. Army Medical
Research Institute of Infectious Diseases maintain level-D
laboratories.
Once the Bacillus colonies from our patient were iden-
tified as catalase positive, nonhemolytic, nonmotile gram-
positive rods, the organism was transported to the New
York City Department of Health laboratory for further test-
ing, as mandated by LRN. Although the patient’s symp-
toms did not correlate with classic anthrax disease, a fatal
case of inhalational anthrax mimicking intraabdominal
sepsis had been recently reported (21). The organism iso-
lated in our patient was identified as B. megaterium, a fre-
quent blood culture contaminant but rare cause of menin-
gitis, brain abscess, and catheter-related bacteremia. The
patient’s strain showed a positive reaction to the CAP-DFA
assay. Arecent study (16) also reported one B. megaterium
strain (out of 11 strains) with a positive reaction to the
CAP-DFA assay. This study analyzed a total of 230 B.
anthracis isolates; 228 and 229 were positive by CW-DFA
and CAP-DFA assays, respectively. A total of 56 B. non-
anthracis strains were also tested; 10 B. cereus and 2 B.
thuringiensis were positive by the CW-DFAassay, and 1 B.
megaterium strain was positive by CAP-DFA. Analysis of
the combined DFA results identified 227 of 230 B.
anthracis  isolates; all 56 strains of the other Bacillus
species were negative (16). 
A nonhemolytic, nonmotile Bacillus should be highly
suspicious for B. anthracis. However, species like B.
cereus subsp. mycoides, B. megaterium, B. firmus, and B.
circulans can also be nonhemolytic and nonmotile. The
community laboratory is limited in differentiating these
species, which can lead to delays in diagnosis and response
to potential terrorist events. This case emphasizes the need
for local (level A) laboratories to increase their potential to
differentiate nonmotile, nonhemolytic Bacillus in order to
secure a rapid preliminary diagnosis and avoid unneces-
sary costly treatment. The combined DFA assay would be
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firmation of B. anthracis cultures within 3 to 6 hours. The
assay specificity is similar to the highest levels achieved
by PCR assays, and its sensitivity is similar to that of cul-
ture or perhaps considerably greater if the patient is receiv-
ing antimicrobial agents (16). 
Dr. Dib is a fellow in training in hematology/oncology at the
University of Rochester-Strong Memorial Hospital in New York.
His research interests include the relationship of infectious agents
and carcinogenesis.
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Instructions for Infectious Disease Authors
Dispatches. 
Articles should be 1,000–1,500 words and need not be
divided into sections. If subheadings are used, they should
be general, e.g., “The Study” and “Conclusions.” Provide a
brief abstract (50 words); references (not to exceed 15);
figures or illustrations (not to exceed two); and a brief
biographical sketch of first author—both authors if only
two. Dispatches are updates on infectious disease trends
and research. The articles include descriptions of new
methods for detecting, characterizing, or subtyping new or
reemerging pathogens. Developments in antimicrobial
drugs, vaccines, or infectious disease prevention or elimi-
nation programs are appropriate. Case reports are also wel-
come. 
Commentaries. Thoughtful discussions (500–1,000 words)
of current topics. Commentaries may contain references
but should not include figures or tables.